Science Corporation首席执行官Max Hodak宣布，公司已成功将视力修复芯片PRIMA植入首位斯塔加特病患者体内1。该患者于5月在澳大利亚悉尼眼科医院接受手术1，植入的芯片规格为2毫米×2毫米，位于眼球后部1。术后康复过程中，患者首次看到一个字母，第二次则能够读出一个单词1。
斯塔加特病是一种导致全球约150,000人失明的疾病1。虽然PRIMA芯片已在欧洲上市用于治疗地理萎缩患者1，但这次植入标志着该技术首次用于斯塔加特病患者的临床应用。Hodak表示，公司正在推进下一代芯片的开发，计划在一年内进行人体试验1，并目标在未来五年内接近原生视觉清晰度1。此外，Science Corporation还计划将脑机接口技术应用于神经退行性疾病和中风的治疗1。
Science Corporation has successfully implanted its PRIMA vision-restoration chip in its first patient with Stargardt disease, according to an announcement by Chief Executive Officer Max Hodak.1 The surgical procedure took place in May at the Sydney Eye Hospital in Australia.1 During initial recovery assessments, the patient was able to perceive a letter following the first examination and read an entire word at the second evaluation.1
The PRIMA chip, measuring 2 millimeters by 2 millimeters, was positioned at the back of the eye.1 Approximately 150,000 people worldwide have lost their vision due to this degenerative eye disease.1 Hodak indicated that the company is advancing development of a next-generation implant, with human trials expected to begin within one year.1 He further stated that within five years, the company aims to achieve visual clarity approaching that of normal, unimpaired vision.1 Beyond vision restoration, Science Corporation plans to apply its brain-computer interface technology to treating neurodegenerative diseases and stroke.1 The PRIMA chip has already been commercialized in Europe for patients with geographic atrophy, another retinal condition.1
评论
还没有评论，欢迎留下第一条。